STEVENSON, Md., Aug. 01, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Arconic Inc. (NYSE:ARNC) (“Arconic” or the “Company”) securities during the period between November 4, 2013 and June 26, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 11, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Arconic securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company was selling Reynobond PE for use in construction projects where it was known to be unsafe and presented a fire hazard.
According to the complaint, following June 24, 2017 and June 26, 2017 reports regarding the flammable panels, the value of Arconic shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Arconic securities purchased on or after November 4, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 



